BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Virogen, Inc.'s Newsletter to Shareholders Delieanates Company's Expansion Into Worldwide Markets


4/20/2009 11:06:57 AM

MINNEAPOLIS, MN--(Marketwire - April 20, 2009) - Virogen, Inc. (PINKSHEETS: VRGN), the developer and patent holder of a revolutionary vaccine to combat the deadly Newcastle disease that kills chickens worldwide, is making public the following letter that CEO Paul Hogan has written to the company's shareholders.

Dear Shareholders:

First I would like to extend my thanks to all those who are participating in the support and success of the company. For all of you, as well as those new to the company, I would like to offer the following update:

Virogen received the manufacturing and export license approval under European Union regulatory standards at the end of July 2008. Once the license was granted, the company aggressively began pursuing registrations and contracts with distributors worldwide. To date, the company has signed contracts with two major distributors in the Middle East and in Asia, and these existing contracts are expected to be operational by July 1, 2009.

Virogen presently has $400,000 in purchase orders from these distributors and is in the final stages of obtaining registrations in the countries where these distributors are doing business. This process normally takes two years, but the company has been placed on the fast track due to the government's recognition of the urgent need and producer support for Virogen's Innovo Newcastle Vaccine.

At this time contracts are being reviewed by several other distributors and registrations are being pursued in Thailand, Indonesia, India, Brazil, Russia, and China to name just a few of the markets being cultivated simultaneously. By the second quarter of 2010, it is anticipated that the aforementioned markets and many others will be utilizing Virogen's vaccine.

Finally the company is implementing an aggressive R&D program to develop new products it can introduce to the marketplace in 2010. Beginning in the second half of 2008 and continuing through the first quarter of 2009, Virogen has successfully executed a transition from a purely R&D company to a commercial enterprise. The company looks forward to continued success as it pursues this strategy and successfully executes its business model worldwide.

Respectfully,
Paul Hogan
Chief Executive Officer
Virogen Inc.

Investors and potential investors are invited to call Paul Hogan, CEO Virogen, Inc. at (415) 367-4058 to request a copy of the company's complete business plan.

Forward-Looking Statements:

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Virogen, Inc. and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.


Paul Hogan
CEO
Virogen, Inc.
(415) 367-4058



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES